Stocks News

LAST PRICE
0.0119
TODAY'S CHANGE (%)
0.0000 (0.0000%)

Bid / Lots
---/ ---
Ask / Lots
---/ ---
Open / Previous Close
--- / 0.0119
Day Range
---
52 Week Range
Low 0.0080
High 0.0671
Volume
---
below average

Search Criteria

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Company	Country	Symbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

Oct 31, 2024
- Psyence Group Announces Closing of Previously Announced Disposal of its Stake in PsyLabs, from 9:30AM ET on Thursday Oct 31, 2024 by Dow Jones
  9:30AM ET on Thursday Oct 31, 2024 by Dow Jones
  Companies Mentioned: PSYG, PBM
  
  Neither of the parties referenced in this news release make any medical, treatment or health benefit claims about the proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding psilocybin, psilocybin analogues, or other psychedelic compounds or nutraceutical products. The efficacy of such products has not been confirmed by approved research. There is no assurance that the use of psilocybin, psilocybin analogues, or other psychedelic compounds or nutraceuticals can diagnose, treat, cure or prevent any disease or condition. Vigorous scientific research and clinical trials are needed. Neither of the parties referenced in this news release has conducted clinical trials for the use of the proposed products. Any references to quality, consistency, efficacy, and safety of potential products do not imply that any of the parties referenced in this news release verified such in clinical trials or that such parties will complete such trials. If the parties cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on such parties' performance and operations.
- Press Release: Psyence Biomedical Announces Closing of Previously Announced Acquisition of Psyence Group's Stake in PsyLabs, from 7:30AM ET on Thursday Oct 31, 2024 by Dow Jones
  7:30AM ET on Thursday Oct 31, 2024 by Dow Jones
  Companies Mentioned: PSYG, PBM
Oct 25, 2024
- Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Announces Recruitment of Second Clinical Trial Site for Ongoing Phase IIb Clinical Trial of Nature-Derived Psilocybin for Adjustment Disorder in Palliative Care, from 9:42AM ET on Friday Oct 25, 2024 by Dow Jones
  9:42AM ET on Friday Oct 25, 2024 by Dow Jones
  Companies Mentioned: PSYG, PBM
  
  Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Announces Recruitment of Second Clinical Trial Site for Ongoing Phase IIb Clinical Trial of Nature-Derived Psilocybin for Adjustment Disorder in Palliative Care
Oct 14, 2024
- Psyence Group Enters into Debt-for-Equity Swap Agreement with its NASDAQ-Listed Associate, Psyence Biomedical, from 10:43AM ET on Monday Oct 14, 2024 by Dow Jones
  10:43AM ET on Monday Oct 14, 2024 by Dow Jones
  Companies Mentioned: PSYG, PBM
  
  Psyence Group Enters into Debt-for-Equity Swap Agreement with its NASDAQ-Listed Associate, Psyence Biomedical
  
  TORONTO, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Psyence Group Inc ("Psyence Group" or the "Company") (CSE: PSYG) hereby announces that it has entered into a debt-for-equity swap agreement (the "Debt Swap Agreement") with its NASDAQ-listed associate, Psyence Biomedical Ltd (NASDAQ: PBM) ("PBM" or "Psyence Biomed"), pursuant to which Psyence Biomed has agreed to issue to the Company 2,075,920 Psyence Biomed common shares at a deemed price of US$0.50 per common share, in exchange for the discharging of a portion of the debt repayment obligation due under a promissory note, dated January 25, 2024, issued by Psyence Biomed to the Company in connection with Psyence Biomed's listing of its common shares on the NASDAQ in January 2024 ("Debt Swap"). In the event that the average VWAP of Psyence Biomed common shares for the ten trading days prior to January 15, 2025 is lower than US$0.50, Psyence Biomed will be required to make a "make whole payment" in cash or common shares, as set forth in the Debt Swap Agreement. Psyence Biomed has agreed to register the resale of the common shares within 60 days of the issuing of such common shares.
- Press Release: Psyence Group Enters into Debt-for-Equity Swap Agreement with its NASDAQ-Listed Associate, Psyence Biomedical, from 10:43AM ET on Monday Oct 14, 2024 by Dow Jones
  10:43AM ET on Monday Oct 14, 2024 by Dow Jones
  Companies Mentioned: PSYG, PBM
  
  Psyence Group Enters into Debt-for-Equity Swap Agreement with its NASDAQ-Listed Associate, Psyence Biomedical
  
  TORONTO, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Psyence Group Inc ("Psyence Group" or the "Company") (CSE: PSYG) hereby announces that it has entered into a debt-for-equity swap agreement (the "Debt Swap Agreement") with its NASDAQ-listed associate, Psyence Biomedical Ltd (NASDAQ: PBM) ("PBM" or "Psyence Biomed"), pursuant to which Psyence Biomed has agreed to issue to the Company 2,075,920 Psyence Biomed common shares at a deemed price of US$0.50 per common share, in exchange for the discharging of a portion of the debt repayment obligation due under a promissory note, dated January 25, 2024, issued by Psyence Biomed to the Company in connection with Psyence Biomed's listing of its common shares on the NASDAQ in January 2024 ("Debt Swap"). In the event that the average VWAP of Psyence Biomed common shares for the ten trading days prior to January 15, 2025 is lower than US$0.50, Psyence Biomed will be required to make a "make whole payment" in cash or common shares, as set forth in the Debt Swap Agreement. Psyence Biomed has agreed to register the resale of the common shares within 60 days of the issuing of such common shares.

No documents available

Psyence Group Inc
OTC Pink - Current Information:PSYGFUnited StatesView on Canadian Exchange

Search Criteria

Oct 31, 2024

Psyence Group Announces Closing of Previously Announced Disposal of its Stake in PsyLabs, from 9:30AM ET on Thursday Oct 31, 2024 by Dow Jones

Press Release: Psyence Biomedical Announces Closing of Previously Announced Acquisition of Psyence Group's Stake in PsyLabs, from 7:30AM ET on Thursday Oct 31, 2024 by Dow Jones

Oct 25, 2024

Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Announces Recruitment of Second Clinical Trial Site for Ongoing Phase IIb Clinical Trial of Nature-Derived Psilocybin for Adjustment Disorder in Palliative Care, from 9:42AM ET on Friday Oct 25, 2024 by Dow Jones

Oct 14, 2024

Psyence Group Enters into Debt-for-Equity Swap Agreement with its NASDAQ-Listed Associate, Psyence Biomedical, from 10:43AM ET on Monday Oct 14, 2024 by Dow Jones

Press Release: Psyence Group Enters into Debt-for-Equity Swap Agreement with its NASDAQ-Listed Associate, Psyence Biomedical, from 10:43AM ET on Monday Oct 14, 2024 by Dow Jones

Peers Headlines